About all

Sibo forums. Natural SIBO Treatment Protocols: Effective Solutions for Small Intestinal Bacterial Overgrowth

by alexxlab

What is SIBO and why is it so difficult to diagnose. How does SIBO affect digestion and overall health. What are the most effective natural treatment protocols for SIBO. Why do many SIBO patients experience frequent relapses. How can underlying causes of SIBO be addressed for long-term relief.

Understanding Small Intestinal Bacterial Overgrowth (SIBO)

Small Intestinal Bacterial Overgrowth (SIBO) is a complex digestive disorder characterized by an abnormal proliferation of bacteria or archaea in the small intestine. This overgrowth interferes with normal digestion processes, leading to a range of uncomfortable and often debilitating symptoms.

How does SIBO develop? The condition occurs when bacteria or archaea, which are typically found in larger numbers in the large intestine, begin to colonize the small intestine in excessive amounts. These microorganisms compete with the host for nutrients, fermenting food before it can be properly digested and absorbed by the body.

What are the key differences between bacterial and archaeal overgrowth? While SIBO has been used as an umbrella term for both types of overgrowth, experts now distinguish between them:

  • Bacterial overgrowth: Produces hydrogen gas during fermentation
  • Archaeal overgrowth: Produces methane gas and is now referred to as Intestinal Methanogen Overgrowth (IMO)
  • Some bacteria can also produce hydrogen sulfide gas

The Diagnostic Challenges of SIBO

Despite its prevalence, SIBO remains notoriously underdiagnosed. Why is SIBO so difficult to identify? Several factors contribute to this diagnostic challenge:

  1. Symptom overlap with other digestive disorders, particularly Irritable Bowel Syndrome (IBS)
  2. Lack of awareness among many healthcare providers
  3. Limited availability of accurate testing methods
  4. Variability in symptom presentation among patients

How does SIBO relate to IBS? Research suggests that SIBO may be a primary cause of IBS in many cases. With approximately 11% of the global population suffering from IBS, the potential impact of improved SIBO diagnosis and treatment is significant.

The Impact of SIBO on Digestive Health and Overall Wellness

SIBO can have far-reaching effects on a person’s health and quality of life. What are the primary symptoms and consequences of untreated SIBO?

  • Bloating and abdominal distension
  • Altered bowel habits (diarrhea, constipation, or both)
  • Abdominal pain and discomfort
  • Nutrient deficiencies, particularly vitamin B12
  • Fatigue and weakness
  • Leaky gut syndrome
  • Potential mental confusion in advanced cases

How does SIBO lead to nutrient deficiencies? The overgrowth of bacteria or archaea can damage the intestinal wall lining, compromising its ability to absorb nutrients effectively. This can result in poor absorption of fats, carbohydrates, and proteins, as well as various vitamins and minerals.

Natural SIBO Treatment Protocols: A Comprehensive Approach

Effectively treating SIBO requires a multifaceted approach that addresses both the overgrowth itself and the underlying factors contributing to its development. What are some of the most promising natural treatment protocols for SIBO?

1. Dietary Modifications

Implementing specific dietary changes can help starve the overgrown bacteria and reduce symptoms. Which diets have shown promise in managing SIBO?

  • Low FODMAP diet
  • Specific Carbohydrate Diet (SCD)
  • Elemental Diet
  • SIBO Specific Food Guide

2. Herbal Antimicrobials

Natural antimicrobial agents can be effective in reducing bacterial overgrowth. What are some commonly used herbal treatments for SIBO?

  • Berberine
  • Oregano oil
  • Allicin (from garlic)
  • Neem
  • Cinnamon

3. Prokinetics

Improving gut motility is crucial for preventing SIBO recurrence. Which natural prokinetics can help enhance gut motility?

  • Ginger
  • Iberogast
  • Artichoke leaf extract
  • Triphala

4. Biofilm Disruptors

Biofilms can protect harmful bacteria from treatment. What natural substances can help break down these protective barriers?

  • N-acetyl cysteine (NAC)
  • Enzymes (such as nattokinase or serrapeptase)
  • Lauricidin

Addressing Root Causes: The Key to Long-Term SIBO Management

To achieve lasting relief from SIBO, it’s essential to identify and address the underlying factors contributing to its development. What are some common root causes of SIBO?

  • Impaired gut motility
  • Structural abnormalities in the digestive tract
  • Compromised immune function
  • Chronic stress
  • Certain medications (e.g., proton pump inhibitors)
  • Hypothyroidism and other endocrine disorders

How can these underlying issues be addressed? A comprehensive treatment plan may include:

  1. Stress reduction techniques (meditation, yoga, mindfulness)
  2. Targeted supplementation to support gut healing and motility
  3. Addressing hormonal imbalances
  4. Identifying and treating co-existing conditions
  5. Lifestyle modifications to support overall gut health

The Role of Functional Medicine in SIBO Treatment

Functional medicine practitioners often play a crucial role in diagnosing and treating SIBO. How does the functional medicine approach differ from conventional treatment methods?

Functional medicine emphasizes:

  • Comprehensive testing to identify underlying imbalances
  • Personalized treatment protocols based on individual patient needs
  • Addressing root causes rather than just managing symptoms
  • Integration of natural and conventional therapies as needed
  • Ongoing support and monitoring to prevent relapse

Preventing SIBO Recurrence: Strategies for Long-Term Success

Given the high relapse rates associated with SIBO, developing a strategy for long-term management is crucial. What are some effective ways to prevent SIBO recurrence?

  1. Maintain a balanced, gut-friendly diet
  2. Support healthy gut motility through diet, exercise, and supplements
  3. Manage stress levels
  4. Address any underlying health conditions
  5. Use prokinetics as recommended by a healthcare provider
  6. Regular follow-up testing to monitor bacterial levels
  7. Implement a gut-healing protocol to repair intestinal damage

The Future of SIBO Research and Treatment

As awareness of SIBO grows within the medical community, ongoing research is shedding light on new treatment approaches and diagnostic methods. What are some promising areas of SIBO research?

  • Development of more accurate and accessible testing methods
  • Investigation of the role of the gut microbiome in SIBO development
  • Exploration of targeted probiotic therapies
  • Research into the connection between SIBO and other health conditions
  • Refinement of dietary protocols for SIBO management

How might these advancements impact SIBO treatment in the future? As our understanding of SIBO evolves, we can expect more personalized and effective treatment protocols, improved diagnostic accuracy, and potentially even preventive strategies for high-risk individuals.

Navigating SIBO Treatment: Tips for Patients

For individuals struggling with SIBO, the path to diagnosis and effective treatment can be challenging. What steps can patients take to advocate for their health and find appropriate care?

  1. Educate yourself about SIBO and its symptoms
  2. Keep a detailed symptom journal to share with healthcare providers
  3. Seek out practitioners experienced in treating SIBO
  4. Be prepared to discuss your full health history, including any previous digestive issues
  5. Consider working with a multidisciplinary team (e.g., gastroenterologist, functional medicine practitioner, nutritionist)
  6. Stay informed about new research and treatment options
  7. Connect with support groups or online communities for SIBO patients

How can patients best prepare for their appointments with SIBO specialists? Compile a comprehensive list of symptoms, medications, supplements, and dietary habits to provide your healthcare provider with a complete picture of your health status.

The Importance of a Holistic Approach to SIBO Management

Effectively managing SIBO requires more than just addressing the bacterial overgrowth itself. Why is a holistic approach crucial for long-term success?

A comprehensive SIBO management plan should consider:

  • Gut health and microbiome balance
  • Nutrient deficiencies and absorption issues
  • Immune system function
  • Stress management and mental health
  • Sleep quality and circadian rhythm regulation
  • Physical activity and exercise habits
  • Environmental factors and toxin exposure

How do these various factors interact to influence SIBO development and recovery? By addressing multiple aspects of health simultaneously, patients can create a more robust foundation for healing and reduce the likelihood of SIBO recurrence.

Customizing SIBO Treatment: The Importance of Individualized Care

While there are general principles for treating SIBO, the most effective approach often involves tailoring treatment to each patient’s unique circumstances. Why is personalized care so important in SIBO management?

Factors that may influence treatment decisions include:

  • The specific type of overgrowth (hydrogen, methane, or hydrogen sulfide-producing)
  • The severity and duration of symptoms
  • Co-existing health conditions
  • Previous treatment attempts and their outcomes
  • Individual food sensitivities and dietary preferences
  • Lifestyle factors and stress levels
  • Genetic predispositions

How can healthcare providers determine the most appropriate treatment protocol for each patient? A thorough initial assessment, including comprehensive testing and a detailed patient history, is crucial for developing an effective, personalized treatment plan.

The Role of Gut-Brain Connection in SIBO Management

The intricate relationship between the gut and the brain plays a significant role in digestive health, including SIBO development and management. How does the gut-brain axis influence SIBO?

Key aspects of the gut-brain connection in SIBO include:

  • The impact of stress on gut motility and bacterial balance
  • The influence of gut health on mood and cognitive function
  • The role of the vagus nerve in regulating digestive processes
  • The potential for psychological interventions to support SIBO treatment

What strategies can be employed to support the gut-brain axis during SIBO treatment? Incorporating stress reduction techniques, mindfulness practices, and potentially even psychotherapy can complement other treatment modalities and improve overall outcomes.

Integrating Conventional and Alternative Therapies for SIBO

While natural treatment protocols can be highly effective for many SIBO patients, some cases may benefit from a combination of conventional and alternative approaches. How can these different treatment modalities be integrated effectively?

Potential combination strategies include:

  • Using herbal antimicrobials in conjunction with targeted probiotics
  • Alternating between pharmaceutical and herbal treatments to prevent resistance
  • Combining dietary interventions with medication or supplement protocols
  • Incorporating complementary therapies such as acupuncture or hypnotherapy

What are the potential benefits and challenges of integrating multiple treatment approaches? While a comprehensive approach can address various aspects of SIBO simultaneously, it requires careful coordination and monitoring to avoid potential interactions or overwhelm.

The Impact of SIBO on Quality of Life: Addressing the Emotional Toll

Living with SIBO can have significant emotional and psychological impacts on patients. How does SIBO affect mental health and overall well-being?

Common emotional challenges faced by SIBO patients include:

  • Anxiety and depression related to chronic symptoms
  • Social isolation due to dietary restrictions and unpredictable symptoms
  • Frustration with the diagnostic process and treatment failures
  • Body image issues related to bloating and weight changes
  • Fatigue and reduced ability to engage in daily activities

What strategies can help patients cope with the emotional aspects of SIBO? Incorporating mental health support, joining support groups, and practicing self-compassion can be valuable components of a comprehensive SIBO management plan.

Emerging Trends in SIBO Research and Treatment

As our understanding of SIBO continues to evolve, new areas of research are emerging that may shape future treatment approaches. What are some of the most exciting developments in SIBO research?

  • Investigation of the role of the small intestinal microbiome in health and disease
  • Exploration of novel biomarkers for more accurate SIBO diagnosis
  • Development of targeted prebiotics and probiotics for SIBO management
  • Research into the connection between SIBO and other systemic diseases
  • Advancements in understanding the genetic factors influencing SIBO susceptibility

How might these research trends impact SIBO treatment in the coming years? As our knowledge expands, we can anticipate more precise diagnostic tools, targeted therapies, and potentially even preventive strategies for individuals at high risk of developing SIBO.

In conclusion, while SIBO remains a challenging condition to diagnose and treat, the growing body of research and clinical experience offers hope for more effective management strategies. By adopting a comprehensive, individualized approach that addresses both the overgrowth itself and its underlying causes, patients can achieve lasting relief and improved quality of life. As awareness of SIBO continues to grow within the medical community, we can look forward to further advancements in diagnosis, treatment, and prevention of this complex digestive disorder.

Why SIBO Is So Difficult to Diagnose

In 2017, shortly after she turned 32, Phoebe Lapine had just spent the previous three years overhauling her health to make up for her ailing thyroid, the result of unchecked Hashimoto’s thyroiditis. She was following a gluten-free diet, drinking kombucha and taking prebiotics, and finally feeling her best when she noticed peculiar gut symptoms starting to rear their head: burping during meals, stomach discomfort, and a bloated belly that simply would not deflate. She turned to a functional doctor who quickly gave her a diagnosis: small intestinal bacterial overgrowth (SIBO), a gut condition not uncommon for hypothyroid patients.

Lapine, who lives in New York, had never heard of it, nor had her endocrinologist warned of the possibility of developing it. The diagnosis was a relief: “It’s not all in my head; the bloating is just sticking to my body like an inner tube,” Lapine, now 36, remembers thinking. But treatment proved to be an odyssey in and of itself. It would take six weeks of antimicrobial medicines and another six months of a restricted diet for her digestion to feel normal again, and for the bloat to finally go away. Lapine, a food and health writer and chef, chronicled her SIBO journey and shared SIBO-appropriate recipes on her blog and podcast in early 2018. That’s when she learned how lucky she’d been.

“I’ve gotten many, many messages and emails from really sick, desperate people. They reach out from all over the world and are like, ‘No one here where I live knows what this is,’” Lapine says. She answered the first few notes, but when the avalanche didn’t let up, she set up an automatic response with links to online resources.

SIBO is a notoriously underdiagnosed condition, despite research suggesting it may be a chief cause of irritable bowel syndrome (IBS). Approximately 11% of people worldwide suffer from IBS, a “wastebasket diagnosis” many patients with an array of digestive issues are given when doctors can’t pinpoint a more precise cause. Their symptoms can be managed through diet and a handful of supplements and medications, but for a long time, a cure was considered to be out of the question. “People were relegated to ‘learn to live with it.’ When SIBO came along, it really offered some cures and solutions,” says Dr. Nirala Jacobi, a naturopathic doctor whose online platform “The SIBO Doctor” offers courses on the disorder for both practitioners and patients. But although Jacobi and others have led an awareness crusade, many practices fall short when it comes to SIBO diagnosis and treatment. “I still hear from patients every day that they go to the gastroenterologist and it’s still not being recognized,” says Jacobi.

More from TIME

SIBO is the abnormal and prolific growth of either bacteria or archaea—a single-celled organism older than bacteria—in the small intestine. The bacteria or archaea interfere with normal digestion by competing with patients for food. Instead of allowing the small intestine to digest food and release nutrients into the bloodstream, the bacteria or archaea get there first and ferment the food. In the fermentation process, the bacteria release hydrogen, and the archaea release methane, creating the appearance of bloating. Although SIBO has served as the umbrella term for both kinds of overgrowth, experts now prefer to differentiate between them and refer to archaea excess as intestinal methanogen overgrowth, or IMO. Certain bacteria can also produce another gas, hydrogen sulfide, but this type of SIBO does not have its own name. In addition to bloating, fermentation can create a range of IBS issues: usually diarrhea from hydrogen and hydrogen sulfide production, and constipation from methane, although there can be both or neither. Over time, in addition to bowel discomfort, gas production leads to poor fat, carbohydrate, and protein absorption by damaging the intestinal wall lining, creating what’s called “leaky gut.” This also causes vitamin deficiencies, the most acute of which are B-12 deficiencies, leading to weakness and fatigue (and in advanced cases, mental confusion).

Read More: What We Know About Leaky Gut Syndrome

Understanding how and why bacteria or archaea start to overgrow in the small intestine is crucial to treating SIBO and IMO. Although they are digestive disorders, they’re almost always a symptom of another underlying issue: motility dysfunction, or the slow transit of food through the small intestine.

Getting to the root cause

By the time patients call up Dr. David Borenstein’s clinic at Manhattan Integrative Medicine, they’ve consulted three GIs before him, on average, without success. Either treatments were ineffective, or after a temporary reprieve, the SIBO or IMO relapsed. According to some studies, relapse rates are as high as 45%.

“Most of the people who do treat it are gastroenterologists,” says Borenstein, an integrative and functional doctor. “They’ll give you an antibiotic. A lot of the time, it helps, but the SIBO will come right back because they’re not treating the root cause of the problem. ”

Diagnosing SIBO and IMO is simple. A breath test is a noninvasive procedure that measures hydrogen and methane gas levels (hydrogen sulfide too, depending on the kind of test) by having patients blow into plastic tubes or bags every 30 minutes for three hours after ingesting a lactulose substrate. Narrowing down the conditions underlying SIBO and IMO may require a few more tests, but a patient history is the best place to start.

A bad episode of food poisoning—or several—can have damaged the patient’s migrating motor complex (MMC), a system that sweeps the small intestine clean like a dishwasher every 90 minutes and which, if impaired, may leave food debris and bacteria behind, allowing them to multiply. The IBS Smart test looks in the blood for anti-CdtB and anti-vinculin, antibodies produced to fight food poisoning. Their presence can indicate post-infectious IBS and suggest that the MMC has been weakened.

Proton pump inhibitors—a common reflux medication that decreases the amount of acid the stomach produces—can have compromised the stomach’s capacity to kill bacteria. In that case, stomach acid levels should be checked. An underperforming thyroid can have slowed a patient’s MMC, so a full thyroid panel ought to be done. Abdominal surgery—a hysterectomy, a laparoscopy to explore possible endometriosis, a hernia—can have produced scar tissue on the small intestine wall that pinches the intestine and obstructs flow, like a kink in a garden hose. Imaging and further exploration can detect that.

Then a solution can be tailored to the patient. Many involve prescribing a prokinetic agent, a medication that enhances motility.

In the meantime, the excess bacteria and archaea can be eliminated one of three ways. The first option many doctors opt for is a two-week regimen of antibiotics—specifically rifaximin, the first and only U.S. Food and Drug Administration–approved IBS drug, for SIBO, or a combination of rifaximin with either neomycin or metronidazole for IMO, since archaea resist rifaximin alone. For a gentler approach, some practitioners prefer to prescribe herbal antimicrobials such as allicin, oregano, berberine, neem, and cinnamon for four to six weeks. For especially recalcitrant cases, some resort to the elemental diet, a liquid formula of predigested nutrients that gives the digestive tract a break, starving the bacteria or archaea in the process. The elemental diet is the nuclear option, as it’s the most challenging one for patients, considering they can’t eat solid food or drink anything besides water for two to three weeks.

A medical and holistic alliance

The origins of SIBO research trace back to our improved understanding of the microbiome and, specifically, to advances presented by Dr. Mark Pimentel, a gastroenterologist and executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai Medical Center. In 1999—before the term microbiome had even gone mainstream—Pimentel published a paper showing that IBS was not a psychological disorder, as was commonly believed at the time; rather, it was the result of bacterial dysbiosis, or an imbalance of the gut’s microbial community.

Pimentel and his team at Cedars-Sinai have spent the past two decades characterizing the major bacteria in the small intestine. Last year, they published a paper that showed the sequences of the microbiome in the duodenum, the jejunum, the ileum and the colon for the first time. And they homed in on SIBO as an important contributing factor to IBS.

Pimentel’s research caught the attention of Allison Siebecker, a naturopathic physician who had been conducting her own SIBO research and leading awareness campaigns in the holistic community. In 2010, she became one of the first SIBO experts to create an online resource, SIBOinfo.com, with information about the disorder for both physicians and patients. She invited Pimentel to speak at the 2015 SIBO Symposium, an annual conference she’d started organizing a year prior, where the leading U.S. SIBO researchers presented their findings on the disorder and treatments. Pimentel and Siebecker have continued to collaborate since then.

“What’s interesting in the naturopathic community is that they tend to see patients that a lot of Western physicians aren’t able to sort out, and I think that was the case for IBS and SIBO in the beginning,” Pimentel says. “The naturopathic community was seeing a lot of these patients and then also recognizing the treatments sooner than Western medicine.”

While Pimentel pioneered the use of rifaximin as both an IBS and a SIBO treatment, naturopaths like Siebecker had already been touting herbal antimicrobials as an equally effective treatment method.

More awareness

Medical schools are beginning to include more material on the microbiome and dysbiosis, but practicing doctors may not have received that education.

“I trained to be a doctor 20 years ago, and at the time, SIBO was not known,” explains Dr. Ana Esteban, an intensive-care doctor who now specializes in SIBO. “No one talked about the microbiome. So my generation is training the next generation of doctors. Professionals like me are informing ourselves, but we have to specialize on our own, paying for courses out of pocket, finding the time and resources, because we want to. There’s no institutional help.”

As more online resources like Siebecker’s and Jacobi’s crop up, patients are increasingly turning down wastebasket diagnoses and seeking out doctors who will truly probe their digestive issues.

“A lot of people are still told to eat fiber and learn to live with their IBS,” says Jacobi. “Now because of the Internet and social media, people are just not willing to put up with that anymore and are looking for answers.”

Contact us at [email protected].

Small Intestinal Bacterial Overgrowth – PMC

1. Fine D, Schiller LR. American Gastroenterological Association Medical Position Statement. Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1464–1486. [PubMed] [Google Scholar]

2. Corrazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth: reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98:302–309. [PubMed] [Google Scholar]

3. Issacs PE, Kim YS. Blind loop syndrome and small bowel bacterial contamination. Clin Gastroenterol. 1983;12:395–414. [PubMed] [Google Scholar]

4. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999;94:1327–1331. [PubMed] [Google Scholar]

5. Parlesak A, Klein B, Schecher K, et al. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J Am Geriatr Soc. 2003;51:768–773. [PubMed] [Google Scholar]

6. Mitsui T, Kagami H, Kinomoto H, et al. Small bowel bacterial overgrowth and rice malabsorption in healthy and physically disabled older adults. J Hum Nutr Dietet. 2003;16:119–122. [PubMed] [Google Scholar]

7. Teo M, Chung S, Chitti L, et al. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastro Hepatol. 2004;19:904–909. [PubMed] [Google Scholar]

8. Lewis SJ, Potts LF, Malhotra R, et al. Small bowel bacterial overgrowth in subjects living in residential care homes. Age Ageing. 1999;28:181–185. [PubMed] [Google Scholar]

9. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419. [PubMed] [Google Scholar]

10. Riordan SM, McIver CJ, Wakefield D, et al. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol. 2001;96:494–500. [PubMed] [Google Scholar]

11. Haboubi NY, Lee GS, Montgomery RD. Duodenal mucosal morphometry of elderly patients with small intestinal bacterial overgrowth: Response to antibiotics treatment. Age Ageing. 1991;20:29–32. [PubMed] [Google Scholar]

12. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106:615–623. [PubMed] [Google Scholar]

13. Husebye E, Skar V, Hoverstad T, et al. Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. Gut. 1992;33:1331–1337. [PMC free article] [PubMed] [Google Scholar]

14. Iivonen MK, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. Scan J Gastroenterol. 1998;33:63–70. [PubMed] [Google Scholar]

15. Brandi G, Biavati B, Calabrese C, et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol. 2006;101:1756–1761. [PubMed] [Google Scholar]

16. Shindo K, Fukumura M. Effect of h3-receptor antagonists on bile acid metabolism. J Investig Med. 1995;43:170–177. [PubMed] [Google Scholar]

17. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54–59. [PMC free article] [PubMed] [Google Scholar]

18. Lewis SJ, Franco S, Young G, et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10:557–561. [PubMed] [Google Scholar]

19. Vantrappen G, Janssens J, Hellemans J, et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59:1158–1166. [PMC free article] [PubMed] [Google Scholar]

20. Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scan J Gastroenterol. 1996;31:875–880. [PubMed] [Google Scholar]

21. Husebye E, Skar V, Hoverstad T, et al. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology. 1995;109:1078–1089. [PubMed] [Google Scholar]

22. Lacy BE, Koch KL, Crowell MD. Manometry. In: Schuster MM, Crowell MD, Koch KL, editors. Atlas of Gastrointestinal Motility. 2nd ed. Hamilton, B.C.: Decker; 2002. pp. 135–150. [Google Scholar]

23. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–1622. [PubMed] [Google Scholar]

24. Nieuwenhuijs VB, Verheem A, Van Duijvenbode-Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228:188–193. [PMC free article] [PubMed] [Google Scholar]

25. Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98:1362–1370. [PubMed] [Google Scholar]

26. Strid H, Simren M, Stotzer PO, et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67:129–137. [PubMed] [Google Scholar]

27. Wegener M, Adamek RJ, Wedmann B, et al. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci. 1994;39:2209–2215. [PubMed] [Google Scholar]

28. Kaye SA, Lim SG, Taylor M, et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Brit J Rheumatol. 1995;34:265–269. [PubMed] [Google Scholar]

29. Armbrecht U, Lundell L, Lindstedt G, et al. Causes of malabsorption after total gastrectomy with Roux-en-Y reconstruction. Acta Chir Scand. 1988;154:37–41. [PubMed] [Google Scholar]

30. Akhrass R, Yaffe MB, Fischer C, et al. Small-bowel diverticulosis: perceptions and reality. J Am Coll Surg. 1997;184:383–388. [PubMed] [Google Scholar]

31. Swan RW. Stagnant loop syndrome resulting from small-bowel irradiation injury and intestinal by-pass. Gynecol Oncol. 1974;8:441–445. [PubMed] [Google Scholar]

32. Castiglione F, Del Vecchio Blanco G, Rispo A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol. 2000;31:63–66. [PubMed] [Google Scholar]

33. Pignata C, Budillon G, Monaco G, et al. Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes. Gut. 1990;31:879–882. [PMC free article] [PubMed] [Google Scholar]

34. Riordan SM, McIver CJ, Wakefield D, et al. Serum immunoglobulin and soluble IL-2 receptor levels in small intestinal overgrowth with indigenous gut flora. Dig Dis Sci. 1999;44:939–944. [PubMed] [Google Scholar]

35. Riordan SM, McIver CJ, Wakefield D, et al. Small intestinal bacterial overgrowth in the symptomatic elderly. Am J Gastroenterol. 1997;92:47–51. [PubMed] [Google Scholar]

36. McLoughlin GA, Hede JE, Temple JG, et al. The role of IgA in the prevention of bacterial colonization of the jejunum in the vagotomized subject. Br J Surg. 1978;65:435–437. [PubMed] [Google Scholar]

37. Wilcox CM, Waites KB, Smith PD. No relationship between gastric pH, small bowel bacterial colonization, and diarrhoea in HIV-1 infected patients. Gut. 1999;44:101–105. [PMC free article] [PubMed] [Google Scholar]

38. Lacy BE, DeLee R. Irritable Bowel Syndrome: A syndrome in evolution. J Clin Gastroenterol. 2005;39:S230–S242. [PubMed] [Google Scholar]

39. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms in irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506. [PubMed] [Google Scholar]

40. Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose, and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21:1391–1395. [PubMed] [Google Scholar]

41. Parisi G, Leandro G, Bottona E, et al. Small intestinal bacterial overgrowth and irritable bowel syndrome [letter] Am J Gastroenterol. 2003;98:2572. [PubMed] [Google Scholar]

42. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose h3 breath test: Comparison with the 14C-d-xylose and healthy controls. Am J Gastroenterol. 2005:1566–1570. [PubMed] [Google Scholar]

43. Pimentel M, Sofler EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639–2643. [PubMed] [Google Scholar]

44. Virally-Monod M, Tielmans D, Kevorkian JP, et al. Chronic diarrhea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth. Diabetes Metab. 1998;24:530–536. [PubMed] [Google Scholar]

45. Urita Y, Ishihara S, Akimoto T, et al. Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth. World J Gastroenterol. 2006;12:3092–3095. [PMC free article] [PubMed] [Google Scholar]

46. Husebye E, Engedal K. The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol. 1992;27:397–404. [PubMed] [Google Scholar]

47. Melkersson M, Andersson H, Bosaeus I, et al. Intestinal transit time in constipated and non-constipated geriatric patients. Scand J Gastroenterol. 1983;18:593–597. [PubMed] [Google Scholar]

48. Tursi A. Gastrointestinal motility disturbances in celiac disease. J Clin Gastroenterol. 2004;38:642–645. [PubMed] [Google Scholar]

49. Tursi A, Brandimarte G, Giorgetti GM. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol. 2003;98:839–843. [PubMed] [Google Scholar]

50. Deitch EA, Sittig K, Li M, et al. Obstructive jaundice promotes bacterial translocation from the gut. Am J Surg. 1990;159:79–84. [PubMed] [Google Scholar]

51. Madrid AM, Cumsille F, Defillippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci. 1997;42:738–742. [PubMed] [Google Scholar]

52. Chang CS, Chen GH, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28:1187–1190. [PubMed] [Google Scholar]

53. Morencos FC, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1995;40:1252–1256. [PubMed] [Google Scholar]

54. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96:2962–2967. [PubMed] [Google Scholar]

55. Bauer TM, Schwacha H, Steinbruckner B, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol. 2002;97:2364–2370. [PubMed] [Google Scholar]

56. Chang CS, Yang SS, Kao CH, et al. Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis. Scand J Gastroenterol. 2001;36:92–96. [PubMed] [Google Scholar]

57. Li YF, Newton TJ, Weisbrodt NW, et al. Intestinal migrating myoelectrical complexes in rats with acute pancreatitis and bile duct ligation. J Surg Res. 1993;55:182–187. [PubMed] [Google Scholar]

58. Van Felius ID, Akkermans LMA, Bosscha K, et al. Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis. Neurogastroenterol Motil. 2003;15:267–276. [PubMed] [Google Scholar]

59. Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin. 1999;15:47–52. [PubMed] [Google Scholar]

60. Hauge T, Persson J, Danielsson D. Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics (heavy drinkers) Digestion. 1997;58:591–595. [PubMed] [Google Scholar]

61. Stotzer PO, Johansson C, Mellstrom D, et al. Bone mineral density in patients with small intestinal bacterial overgrowth. Hepatogastroenterology. 2003;50:1415–1418. [PubMed] [Google Scholar]

62. Saltzman JR, Russell RM. Nutritional consequences of intestinal bacterial overgrowth. Comp Ther. 1994;20:523–530. [PubMed] [Google Scholar]

63. Shindo K, Machinda M, Koide K, et al. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology. 1998;45:1643–1650. [PubMed] [Google Scholar]

64. Wanitschke R, Ammon HV. Effects of dihydroxy bile acids and hydroxyl fatty acids on the absorption of oleic acid in the human jejunum. J Clin Invest. 1978;61:178–186. [PMC free article] [PubMed] [Google Scholar]

65. Gianella RA, Rout WR, Toskes PP. Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome. Gastroenterology. 1974;67:965–974. [PubMed] [Google Scholar]

66. King CE, Toskes PP. Protein-losing enteropathy in the human and experimental rat blind-loop syndrome. Gastroenterology. 1981;80:504–509. [PubMed] [Google Scholar]

67. Welkos SL, Toskes PP, Baer H. Importance of anaerobic bacteria in the cobalamin malabsorption of the experimental rat blind loop syndrome. Gastroenterology. 1981;80:313–320. [PubMed] [Google Scholar]

68. Suter PM, Golner BB, Goldin BR, et al. Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis. Gastroenterology. 1991;101:1039–1045. [PubMed] [Google Scholar]

69. Russell RM, Krasinski SD, Samloff IM, et al. Folic acid malabsorption in atrophic gastritis: Possible compensation by bacterial folate synthesis. Gastroenterology. 1986;91:1476–1482. [PubMed] [Google Scholar]

70. Camilo E, Zimmerman J, Mason JB, et al. Folate synthesized by bacteria in the human upper small intestine is assimilated by the host. Gastroenterology. 1996;110:991–998. [PubMed] [Google Scholar]

71. Romagnuolo J, Schiller, D, Bailey, RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol. 2002;97:1113–1126. [PubMed] [Google Scholar]

72. Riordan SM, McIver CJ, Duncombe VM, et al. Evaluation of the rice breath hydrogen test for small intestinal bacterial overgrowth. Am J Gastroenterol. 2000;95:2858–2864. [PubMed] [Google Scholar]

73. King CE, Toskes PP, Guilarte TR, et al. Comparison of the one-gram d-[14C]xylose breath test to the [14C]bile acid breath test in patients with small-intestine bacterial overgrowth. Dig Dis Sci. 1980;25:53–58. [PubMed] [Google Scholar]

74. Swart GR, van den Berg JW. 13C breath tests in gastroenterological practice. Scand J Gastroenterol Suppl. 1998;225:13–18. [PubMed] [Google Scholar]

75. King CE, Toskes PP. Comparison of the 1 gram 14C-D-xylose, 10 gram lactulose and 80 gram glucose h3 breath test in patients with small intestinal bacterial overgrowth. Gastroenterology. 1986;91:1447–1451. [PubMed] [Google Scholar]

76. Fromm H, Hofmann AF. Breath test for altered bile-acid metabolism. Lancet. 1971;2:621–625. [PubMed] [Google Scholar]

77. Suhr O, Danielsson A, Horstedt P, et al. Bacterial contamination of the small bowel evaluated by breath tests, 75Se-labelled homocholic-tauro acid, and scanning electron microscopy. Scan J Gastroenterol. 1990;25:841–852. [PubMed] [Google Scholar]

78. Gibson GR, Cummings JH, Macfarlane GT, et al. Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut. 1990;31:679–683. [PMC free article] [PubMed] [Google Scholar]

79. Bjorneklett A, Fausa O, Midvedt T. Small-bowel bacterial overgrowth in the postgastrectomy syndrome. Scan J Gastroenterol. 1983;18:277–287. [PubMed] [Google Scholar]

80. Salzberg DM, Levine GM, Lubar C. Impact of age, sex, race, and functional complaints on hydrogen (h3) production. Dig Dis Sci. 1988;33:308–314. [PubMed] [Google Scholar]

81. Hutchinson S, Logan R. The effect of long-term omeprazole on the glucosehydrogen breath test in elderly patients. Age Ageing. 1997;26:87–89. [PubMed] [Google Scholar]

82. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95:982–988. [PubMed] [Google Scholar]

83. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566–1570. [PubMed] [Google Scholar]

84. Rumessen JJ, Gudmand-Hoyer E, Bachmann E, et al. Diagnosis of bacterial overgrowth of the small intestine. Comparison of the 14C-D-xylose breath test and jejunal cultures in 60 patients. Scand J Gastroenterol. 1985;20:1267–1275. [PubMed] [Google Scholar]

85. Stotzer PO, Kilander AF. Comparison of the 1-gram 14C-D-xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. Digestion. 2000;61:165–171. [PubMed] [Google Scholar]

86. Goshal UC, Goshal U, Das K, et al. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome, and its relationship with oro-cecal transit time. Indian J Gastroenterol. 2006;25:6–10. [PubMed] [Google Scholar]

87. Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol. 1996;91:1795–1803. [PubMed] [Google Scholar]

88. Chang CS, Chen GH, Kao CH, et al. Increased accuracy of the carbon-14 Dxylose breath test in detecting small-intestinal bacterial overgrowth by correction with the gastric emptying rate. Eur J Nucl Med. 1995;22:1118–1122. [PubMed] [Google Scholar]

89. Perman JA, Modler S, Barr RG, et al. Fasting breath hydrogen concentration: normal values and clinical application. Gastroenterology. 1984;87:1358–1363. [PubMed] [Google Scholar]

90. Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cis-apride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96:1251–1255. [PubMed] [Google Scholar]

91. Edmunds MC, Chen JD, Soykan I, et al. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998;12:167–174. [PubMed] [Google Scholar]

92. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461–1467. [PubMed] [Google Scholar]

93. Bishop WP. Breath hydrogen testing for small bowel bacterial overgrowth– a lot of hot air? J Pediatr Gastroenterol Nutr. 1997;25:245–246. [PubMed] [Google Scholar]

94. Di Stefano M, Miceli E, Missanelli A, et al. Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Aliment Pharmacol Ther. 2005;21:985–992. [PubMed] [Google Scholar]

95. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14:551–556. [PubMed] [Google Scholar]

96. Castiglione F, Rispo A, Di Girolamo E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;18:1107–1112. [PubMed] [Google Scholar]

97. Attar A, Flourie B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117:794–797. [PubMed] [Google Scholar]

98. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;92:412–419. [PubMed] [Google Scholar]

99. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (Rifaxamin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145:557–563. [PubMed] [Google Scholar]

100. Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina. 2002;62:159–163. [PubMed] [Google Scholar]

101. Stotzer PO, Blomberg L, Conway PL, et al. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD.